

## CHINA

## BIOPHARMACEUTICAL BUSINESS DELEGATION 2026

21–30 May 2026 · Suzhou · Nanjing · Hainan · Nantong

City Industry Profiles · Partner Institution Overview · Key Statistics

## About This Document

This report provides European business leaders with a data-driven overview of the four Chinese cities included in the 2026 Biopharmaceutical Business Delegation. Each city profile presents key industry statistics, competitive strengths, and a structured summary of the organisations you will meet — spanning government investment authorities, leading pharmaceutical and biotechnology companies, world-class research institutions, and major financial institutions.

4

Cities visited

Suzhou · Nanjing · Hainan · Nantong

80+

Partner organisations

Across all four cities

¥362B+

Combined industry output

Suzhou + Nanjing alone, 2024

10 days


Programme duration

21 – 30 May 2026

## Four-City Comparison

The table below summarises key dimensions across all four cities to help you identify the most relevant partnership opportunities for your organisation.

| Dimension            | Suzhou    | Nanjing       | Hainan              | Nantong              |
|----------------------|-----------|---------------|---------------------|----------------------|
| Innovative drugs     | ★★★★★     | ★★★★☆         | ★★★★☆               | ★★★★☆                |
| Manufacturing scale  | ★★★★☆     | ★★★★☆         | ★★★★☆               | ★★★★★                |
| Int'l openness       | ★★★★☆     | ★★★★☆         | ★★★★★               | ★★★★☆                |
| Research strength    | ★★★★☆     | ★★★★★         | ★★★★☆               | ★★★★☆                |
| Policy advantage     | ★★★★☆     | ★★★★☆         | ★★★★★               | ★★★★☆                |
| MNE attraction       | ★★★★★     | ★★★★☆         | ★★★★☆               | ★★★★★                |
| 2024 headline output | ¥152B SIP | ¥210B revenue | +47% pharma imports | BioNTech \$800M base |



中国国际投资促进中心(德国)

China International Investment Promotion Agency (Germany)

中法  
城市  
发展协会  
Association Franco-Chinoise du  
Développement Urbain Durable

# SUZHOU · Jiangsu Province

China's #1-ranked biopharmaceutical industrial park by industrial competitiveness (2024 national evaluation)

## ¥152B

Biomedical output (2023)  
SIP — #1 in Jiangsu

## 24

Listed biomedical cos.  
>50% of Jiangsu total

## 22%

China clinical approvals  
New biologics, 3-year avg.

## 10,000+

Tech firms in SIP  
incl. 3,000+ national hi-tech

### Industry Strengths

| Industry strengths (index 0–100) |                        |    |
|----------------------------------|------------------------|----|
| Innovative drugs                 | <div><div></div></div> | 95 |
| Medical devices                  | <div><div></div></div> | 90 |
| Biotech / Cell Tx                | <div><div></div></div> | 88 |
| Macromol. drugs                  | <div><div></div></div> | 85 |
| CRO / CDMO                       | <div><div></div></div> | 80 |
| Int'l partnerships               | <div><div></div></div> | 92 |

### Key Strategic Advantages

| Key strategic advantages                           |
|----------------------------------------------------|
| ◆ #1 industrial competitiveness — national 2024    |
| ◆ China–Singapore co-founded innovation zone       |
| ◆ 278 km <sup>2</sup> — vast, integrated ecosystem |
| ◆ 30% of China's bio macromolecular drug approvals |
| ◆ 5,000+ foreign enterprises established           |
| ◆ 93 Fortune 500 MNCs present                      |
| ◆ Biobay + Medpark dual-cluster model              |
| ◆ GDP growth >20%/yr — decade of outperformance    |
| ◆ 25-minute bullet train to Shanghai               |

### Partner Institutions in the Delegation

#### Government & Investment

- ▶ **SIP Administrative Committee** *Industrial governance · China–Singapore*
- ▶ **SIP Investment Promotion Bureau** *FDI facilitation · 5,000+ foreign firms*
- ▶ **Suzhou High-Tech Zone Admin. Committee** *Hi-tech district governance*
- ▶ **High-Tech Zone Investment Promotion Bureau** *Investment services*

#### Research & Academia

- ▶ **CAS SIBET** *Chinese Academy of Sciences research institute*
- ▶ **Soochow University Medical College** *Leading medical education & research*
- ▶ **Suzhou BioPharma Association** *Industry coordination body*
- ▶ **Suzhou Medical Device Innovation Center** *Technology commercialisation platform*
- ▶ **Suzhou Biomedical Eng. Innovation Center** *Biomedical R&D hub*

#### Financial Institutions

- ▶ **Bank of China – SIP Branch** *State commercial bank*
- ▶ **Bank of Jiangsu – Suzhou Branch** *Regional innovation financing*

#### Pharmaceutical & Biotech Companies

- ▶ **Innovent Biologics · CStone · Ascentage Pharma** *Listed innovative drug leaders*
- ▶ **JW Therapeutics · Abogen Biosciences** *CAR-T · mRNA therapeutics*
- ▶ **EpimAb Biotherapeutics** *Bispecific antibody platform*
- ▶ **GeneQuantum Healthcare** *Antibody-drug conjugates (ADC)*
- ▶ **Ribo Life Science** *RNA therapeutics & nucleic acid drugs*
- ▶ **Transcenta · Alphamab · TenNor** *Antibody · Oncology · Anti-infective*
- ▶ **Puhe Biopharma · PharmaBlock R&D** *Biopharma · Pharma research services*
- ▶ **Sansure Biotech · Ortho Clinical Diagnostics** *Molecular diagnostics & IVD*

#### Global MedTech (Suzhou Sites)

- ▶ **GE HealthCare Suzhou** *Medical imaging & digital health*
- ▶ **Becton Dickinson (BD) Suzhou** *Infection control & diagnostics*
- ▶ **Fresenius Medical Care Suzhou** *World's largest dialysis provider*
- ▶ **Mindray Suzhou R&D Center** *Patient monitoring & diagnostics*
- ▶ **Lepu Medical Suzhou** *Cardiovascular medical devices*

# NANJING · Jiangsu Province

China's emerging biomedical capital — ¥210B revenue, 1,032 high-tech enterprises, national top-10 park competitiveness

**¥210B**

Industry revenue (2024)  
+5% year-on-year

**1,032**

Hi-tech enterprises  
Biomedical sector

**1,300+**

Life sci. companies  
In Biomedical Valley alone

**70**

Innovative drugs in trials  
Active clinical pipelines

## Industry Strengths

### Industry strengths (index 0–100)

|                      |                        |    |
|----------------------|------------------------|----|
| CAR-T / Cell therapy | <div><div></div></div> | 96 |
| Innovative drugs     | <div><div></div></div> | 90 |
| Gene therapy         | <div><div></div></div> | 88 |
| Academic research    | <div><div></div></div> | 92 |
| CRO / CDMO           | <div><div></div></div> | 85 |
| MedTech devices      | <div><div></div></div> | 78 |

## Key Strategic Advantages

### Key strategic advantages

- ◆ 14.92 km<sup>2</sup> dedicated Biomedical Valley
- ◆ 4 specialist biopharmaceutical universities
- ◆ 30+ top-tier hospitals for clinical research
- ◆ Legend Biotech — world-leading CAR-T (J&J partner)
- ◆ 200+ products in active R&D pipeline
- ◆ Jiangbei New Area — national development zone
- ◆ 136 provincial+ innovation platforms built
- ◆ 35 national 'little giant' specialist SMEs
- ◆ ¥210B industry revenue, growing 5% YoY

## Partner Institutions in the Delegation

### Government & Investment

- ▶ **Nanjing Investment Promotion Bureau** *City-level FDI authority*
- ▶ **Nanjing Municipal Bureau of Commerce** *Trade & cross-border cooperation*
- ▶ **Jiangbei New Area Biopharma Valley** *National development zone · 1,300+ firms*
- ▶ **Nanjing Biomedical Valley** *Full pharma value chain cluster*
- ▶ **Nanjing Biomedical Valley Innovation Center** *Technology incubation platform*

### Research & Academia

- ▶ **Nanjing University Medical School** *Top-tier biomedical research*
- ▶ **Southeast University – Biomedical Eng.** *Interdisciplinary biomedical engineering*
- ▶ **CAS Nanjing Institute of Bioengineering** *Chinese Academy of Sciences*
- ▶ **Nanjing Institute of Pharmaceutical Tech.** *Drug formulation & process R&D*
- ▶ **Jiangsu Pharmaceutical Industry Association** *Provincial coordination body*
- ▶ **Nanjing Biopharmaceutical Industry Assoc.** *City-level industry coordination*
- ▶ **Jiangsu Industrial Tech. Research Inst.** *Life science division — tech transfer*

### Financial Institutions

- ▶ **Bank of China – Nanjing Branch** *State-owned, international operations*
- ▶ **Bank of Jiangsu – Nanjing Branch** *Regional biotech financing*

### Global Pharma Leaders

- ▶ **Legend Biotech** *World-leading CAR-T · J&J partnership*
- ▶ **BeiGene – Nanjing Site** *Global oncology · 190+ country presence*
- ▶ **Hengrui Medicine** *China's top innovative pharma pipeline*
- ▶ **Sincere Pharmaceutical Group** *Oncology · CNS · Autoimmune pioneer*
- ▶ **GenScript Biotech** *Global gene synthesis & cell therapy*
- ▶ **Yangtze River Pharmaceutical Group** *One of China's largest pharma companies*
- ▶ **Innovent Biologics** *Biologics leader — large-scale manufacturing*

### Biotech & CRO/CDMO

- ▶ **Pharmaron Nanjing · ChemPartner** *Global CRO — drug discovery services*
- ▶ **BioDuro Nantong · Porton Pharma** *CRO & CDMO integrated services*
- ▶ **Leads Biolabs · QYuns · Bioheng** *Immunotherapy & antibody biotech*
- ▶ **BioSciKin · Anji Bio-Pharmaceutical** *Antibody drugs · Innovative medicines*
- ▶ **Chia Tai Tianqing · Triastek** *Oncology · 3D-printed pharmaceuticals*
- ▶ **Yuyue Medical · Micro-Tech Medical** *Medical devices · Global distribution*
- ▶ **Medicilon Nanjing · Sanhome** *CRO preclinical · Pharmaceutical mfg.*

# HAINAN FREE TRADE PORT

China's only free trade port — zero-tariff imports, preferential tax, and unique gateway for global pharma market entry

\$208M

Pharma imports (2024)  
+47% year-on-year

\$32M

Med device imports  
+283% YoY surge

2,072

New foreign enterprises  
Established 2024 (+19.8%)

400+

Licensed drugs in Boao  
Types, from 20 countries

## Industry Strengths

### Industry strengths (index 0–100)

|                      |             |    |
|----------------------|-------------|----|
| Market entry policy  | <div></div> | 98 |
| Int'l drug access    | <div></div> | 95 |
| Medical tourism      | <div></div> | 92 |
| Tax incentives       | <div></div> | 96 |
| Pharma manufacturing | <div></div> | 72 |
| FDI growth rate      | <div></div> | 90 |

## Key Strategic Advantages

### Key strategic advantages

- ◆ Zero-tariff raw material imports
- ◆ 15% preferential corporate income tax
- ◆ China's ONLY medical tourism special zone
- ◆ Boao Lecheng — bonded pharma warehouse
- ◆ Fast-track drug registration via real-world data
- ◆ 170+ pharma partners from 20 countries
- ◆ 400+ types of specially licensed drugs
- ◆ Zero restrictions on manufacturing sector FDI
- ◆ \$32M med device imports — up +283% in 2024

## Partner Institutions in the Delegation

### Government & Strategic Platforms

- ▶ **Hainan Int'l Economic Development Bureau** *FTP provincial investment authority*
- ▶ **Haikou National Hi-Tech Zone Pharma Valley** *Pharma industrial cluster*
- ▶ **Hainan Pharmaceutical Industry Association** *Provincial industry body*
- ▶ **Haikou Health Industry Promotion Assoc.** *Healthcare sector development*

### Research & Academic Institutions

- ▶ **Hainan Medical University — Drug Safety Eval.** *Preclinical research & drug toxicology*
- ▶ **Hainan Medical Univ. — Tropical Drug R&D** *Tropical disease drug innovation centre*
- ▶ **Hainan University — School of Pharmacy** *Pharmaceutical education & research*
- ▶ **Hainan Institute for Inspection & Testing** *Regulatory compliance & quality assurance*

### Manufacturing & Innovation Platforms

- ▶ **Optics Valley Biocity Cell CDMO Platform** *Cell therapy CDMO — clinical to commercial*
- ▶ **Haiping Medical Device Industrial Park** *MedTech manufacturing cluster*

### Financial Institutions

- ▶ **Bank of China — Hainan Branch** *State bank · International financial services*
- ▶ **ICBC — Hainan Branch** *World's largest commercial bank*

### Pharmaceutical & Biotech Companies

- ▶ **Qilu Pharmaceutical — Hainan** *Major pharma mfr · Oncology specialist*
- ▶ **Hainan Sincere Pharmaceutical** *Innovative drug manufacturing*
- ▶ **Hainan Haiyao Co.** *Long-established Hainan pharma firm*
- ▶ **Hainan Poly Pharm** *Export-oriented injectable medicines*
- ▶ **Hainan Better Pharmaceutical** *Pharmaceutical manufacturing*
- ▶ **Bloomage Biotech — Hainan Industrial Park** *Hyaluronic acid & bioactive materials*
- ▶ **Bioway Gene Technology** *Genomics & precision diagnostics*
- ▶ **Hainan Susun Biotech** *Biotech & medical applications*
- ▶ **Hainan Weili Medical Technology** *Medical technology innovation*
- ▶ **Xin Kaillian Biotech Hainan** *Biological products & biomedical solutions*
- ▶ **Hainan Hongzheng Biotech** *Biomedical technology & health products*
- ▶ **Hainan Digi Biotech** *Biomedical technology development*

# NANTONG · Jiangsu Province

Rising pharma manufacturing hub — Zhangjiang Pharma Valley integration; home to BioNTech's only China production base

~100

Pharma enterprises  
In Qidong biopharma cluster

¥750M

Bayer investment  
New Qidong supply centre

\$800M

BioNTech acquisition  
BioTheus Nantong facility

18+18+50

Drug/MedTech/Startups  
Full innovation ecosystem

## Industry Strengths

### Industry strengths (index 0–100)

|                      |                        |    |
|----------------------|------------------------|----|
| API / CDMO mfg.      | <div><div></div></div> | 94 |
| CRO services         | <div><div></div></div> | 88 |
| Biologics mfg.       | <div><div></div></div> | 82 |
| MNE partnerships     | <div><div></div></div> | 90 |
| Shanghai integration | <div><div></div></div> | 95 |
| Industrial scale-up  | <div><div></div></div> | 85 |

## Key Strategic Advantages

### Key strategic advantages

- ◆ BioNTech's ONLY production base in China
- ◆ WuXi AppTec anchor — world CRO leader
- ◆ Bayer ¥750M supply centre investment
- ◆ Qidong Life & Health Park — full cycle chain
- ◆ Direct integration with Zhangjiang Pharma Valley
- ◆ Asymchem global CDMO base — full API services
- ◆ Yangtze River estuary — strategic logistics hub
- ◆ Merck, Bayer, WuXi: 3 global MNEs co-located

## Partner Institutions in the Delegation

### Government & Industry Authorities

- ▶ **Nantong Biopharma Industry Association** *City-level coordination body*
- ▶ **Nantong Innovation Zone Life Sci. Centre** *Technology transfer & FDI*
- ▶ **Qidong Biopharma Development Office** *Industrial planning · Qidong cluster*
- ▶ **Jiangsu Biopharma Industry Association** *Province-wide industry body*
- ▶ **Jiangsu Medical Device Industry Assoc.** *MedTech province representation*

### Medical Devices & Diagnostics

- ▶ **Yuyue Medical** *China's leading medical device manufacturer*
- ▶ **Nanjing Micro-Tech Medical** *Minimally invasive diagnostic devices*
- ▶ **Sansure Biotech Nantong** *Molecular diagnostics platforms*

### Financial Institutions

- ▶ **Bank of China – Nantong Branch** *State commercial bank*
- ▶ **Bank of Jiangsu – Nantong Branch** *Regional innovation financing*

### Global Pharma & Manufacturing Leaders

- ▶ **WuXi AppTec – Qidong** *World-leading CRO/CDMO platform*
- ▶ **Asymchem – Nantong** *Global CDMO — process research & API mfg.*
- ▶ **Merck Pharmaceutical Jiangsu** *Global German pharma · China supply network*
- ▶ **Hengrui Medicine** *China's top innovative pharma pipeline*
- ▶ **Innovent Biologics** *Biologics leader — large-scale manufacturing*
- ▶ **Yangtze River Pharmaceutical Group** *One of China's largest pharma enterprises*
- ▶ **GenScript Biotech** *Global gene synthesis & cell therapy*
- ▶ **Pumai Biopharmaceutical Nantong** *Biologics development & manufacturing*
- ▶ **BioDuro Nantong** *CRO — drug discovery & development*
- ▶ **Sword Pharma Nantong** *Active pharmaceutical ingredients (API)*
- ▶ **Nantong Lianya Pharmaceutical** *Pharma formulations manufacturing*
- ▶ **Jiangsu Sennics Biopharma** *Pharmaceutical ingredients & specialty chemicals*
- ▶ **InnoScience Biotech Nantong** *Biotech product development*